{
  "ticker": "LLY",
  "target_date": "2025-05-02",
  "actual_date": "2025-05-02",
  "collected_at": "2025-12-08T11:43:03.278658",
  "price": {
    "open": 820.42,
    "high": 826.8,
    "low": 802.99,
    "close": 818.93115234375,
    "volume": 6059400,
    "change_1d_pct": 3.72,
    "change_7d_pct": -0.7,
    "change_30d_pct": -2.25
  },
  "technicals": {
    "rsi_14": 61.29,
    "sma_20": 794.45,
    "sma_50": 827.51,
    "macd": 11.478,
    "macd_signal": 6.023,
    "macd_histogram": 5.455,
    "bb_upper": 918.6,
    "bb_lower": 670.3,
    "price_vs_sma20_pct": 3.08,
    "price_vs_sma50_pct": -1.04,
    "volume_ratio": 1.28
  },
  "fundamentals": {
    "market_cap": 890392215552,
    "pe_ratio": 48.664135,
    "forward_pe": 43.83208,
    "price_to_book": 37.395897,
    "price_to_sales": 14.984773,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.68,
    "pct_from_52w_low": 59.23
  },
  "macro": {
    "spy": {
      "price": 563.53,
      "change_1d_pct": 1.48,
      "change_7d_pct": 3.67
    },
    "vix": {
      "level": 22.68,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.32
    },
    "dollar_index": {
      "level": 100.0
    },
    "gold": {
      "price": 3231.9
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "Novo Nordisk shares jump as FDA accepts oral Wegovy application",
      "source": "Yahoo",
      "datetime": 1746215316,
      "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company\u2019s New Drug Application for an oral version of Wegovy. If approved, the pill formulation would be the first oral GLP-1 treatment for chronic weight management in adults",
      "url": "https://finnhub.io/api/news?id=c7751ec8e6baa60179bd17828960b2d69a2967066001879807dd52acb188873a"
    },
    {
      "headline": "US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss",
      "source": "Yahoo",
      "datetime": 1746211263,
      "summary": "The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.  U.S.-listed shares of Novo added to session gains and were last up 5.72% at $69.36 following the news.  Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ",
      "url": "https://finnhub.io/api/news?id=4e2d3aa69a0af08a8126c6dbf8dcc252069c78fe3b49a5dbd80f7190e7b767e1"
    },
    {
      "headline": "Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance",
      "source": "Yahoo",
      "datetime": 1746207967,
      "summary": "Eli Lilly (NYSE:LLY) recently experienced a slight decline in share price of 1.38% over the last month. This period coincided with several key events for the company, such as earnings that showed improved sales and net income, overall financial health indicators, and research findings supporting its",
      "url": "https://finnhub.io/api/news?id=b818cb127beb3b1c7e1adde44d11f03c297129239a9665de3c4db4aec6021508"
    },
    {
      "headline": "Trump Says Drug Tariffs Are Coming. Big Pharma Execs Can\u2019t Figure Out How Much to Worry.",
      "source": "Yahoo",
      "datetime": 1746206340,
      "summary": "The Trump administration said in mid-April to expect tariffs on drug imports in a month or so, which puts the deadline sometime in the next few weeks.",
      "url": "https://finnhub.io/api/news?id=15f4a2ff0607c6619e78dabd1dfa023a6f335354b43315ea0fc387f3657e6202"
    },
    {
      "headline": "Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday",
      "source": "Yahoo",
      "datetime": 1746201345,
      "summary": "GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.",
      "url": "https://finnhub.io/api/news?id=363d6b0b46c581ea32db7880525b4209f660ada0563639d2ce3086237f706d2e"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-05-01",
      "description": "lly-20250331.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/lly-20250331.htm"
    },
    {
      "form": "8-K",
      "date": "2025-05-01",
      "description": "lly-20250501.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/lly-20250501.htm"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353361.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000124/xslF345X05/wk-form4_1745353361.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353273.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000122/xslF345X05/wk-form4_1745353273.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353160.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000120/xslF345X05/wk-form4_1745353160.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}